{
    "nctId": "NCT02619929",
    "briefTitle": "Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria",
    "officialTitle": "Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany and Austria (StepUp)",
    "overallStatus": "COMPLETED",
    "conditions": "Non-Small-Cell Lung Cancer, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 108,
    "primaryOutcomeMeasure": "Rate of patients with oral vinorelbine dose increase from \u226460 to \u226580 mg/m\u00b2 during the course of the study",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent of the patient with regard to the pseudonymized documentation and processing of his/her disease data\n* Legally capable male or female NSCLC patient or legally capable female MBC patient; in both situations: \u2265 18 years of age (no upper limit)\n* Presence of any of the following two tumor entities:\n\n  * Advanced NSCLC (stage III or IV)\n  * Anthracycline- and taxane-resistant MBC (stage IV) in women\n* Planned systemic chemotherapy and planned regimen with oral vinorelbine in any palliative setting (decision on treatment must have been made before inclusion in this study); included treatments:\n\n  * Monotherapy or any combination therapy with oral vinorelbine\n  * Inclusion of patients with hybrid-treatment involving i.v. and oral vinorelbine in one treatment cycle is allowed\n\nExclusion Criteria:\n\n* Presence of any contraindication with regard to oral vinorelbine treatment (and with regard to i.v. vinorelbine in case of hybrid-treatment) according to the respective Summary of Product Characteristics (SmPC)\n* Oral vinorelbine based palliative treatment already ongoing or planned oral vinorelbine starting dose of \\>60 mg/m2\n* Presence of a Eastern Cooperative Oncology Group (ECOG) performance status (PS) \\> 2\n* Simultaneous participation in an interventional clinical trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}